HEALTH CATALYST INC (HCAT) Stock Analyst Ratings
USA - NASDAQ:HCAT - US42225T1079 - Common Stock
3.23 USD
-0.05 (-1.52%)
3.23 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 73% to HCAT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.53. This target is 40.35% above the current price.
HCAT was analyzed by 18 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about HCAT.
In the previous month the buy percentage consensus was at a similar level.
HCAT was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-08 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-10-07 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2025-09-05 | BTIG | Reiterate | Neutral -> Neutral |
| 2025-08-29 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-28 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-08-27 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2025-08-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-08 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2025-08-08 | Stifel | Maintains | Hold -> Hold |
| 2025-08-08 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-07-09 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2025-05-08 | Stifel | Maintains | Hold -> Hold |
| 2025-05-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-04-25 | Citigroup | Maintains | Buy -> Buy |
| 2025-04-16 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-04-09 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2025-03-06 | Stephens & Co. | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-27 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-02-27 | Stephens & Co. | Reiterate | Equal-Weight -> Equal-Weight |
| 2025-02-27 | Stifel | Maintains | Hold -> Hold |
| 2025-02-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-01-21 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-01-21 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-01-15 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-01-10 | Citigroup | Maintains | Buy -> Buy |
| 2025-01-08 | Keybanc | Upgrade | Sector Weight -> Overweight |
| 2024-11-26 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-11-14 | Stephens & Co. | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-13 | Citigroup | Maintains | Buy -> Buy |
HEALTH CATALYST INC / HCAT FAQ
What is the price target for HCAT stock?
18 analysts have analysed HCAT and the average price target is 4.53 USD. This implies a price increase of 40.35% is expected in the next year compared to the current price of 3.23.
Can you provide the consensus rating for HEALTH CATALYST INC stock?
The consensus rating for HEALTH CATALYST INC (HCAT) is 73.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed HEALTH CATALYST INC (HCAT)?
The number of analysts covering HEALTH CATALYST INC (HCAT) is 18.